跳至主要内容
临床试验/EUCTR2011-006239-44-NL
EUCTR2011-006239-44-NL进行中(未招募)不适用

An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response(STOPIMAPED) - STOPIMAPED

Dutch Childhood Oncology Group0 个研究点目标入组 60 人开始时间: 2012年10月2日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Pediatric CML patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years.
  • Informed consent needs to be signed.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 12
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Non-CML patients, or CML patients with complete cytogenetic reponse but with a moderate molecular response.

研究者

发起方
Dutch Childhood Oncology Group

相似试验